Alligator Bioscience

Lund, Sweden – 14 August 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announces that it will host a virtual R&D Day on Tuesday, 19 August 2025 at 4 p.m. CEST. The event will provide an in-depth update on Alligator’s R&D pipeline, with a primary focus on its lead candidate mitazalimab, ahead of the upcoming TO 13 warrant exercise period (1–15 September 2025).

During the event, members of Alligator’s executive management and R&D leadership will:

• Provide update on mitazalimab clinical data, as well biomarker findings and Phase 3 readiness.
• Discuss ongoing and planned investigator-initiated trials (IITs) exploring mitazalimab in additional indications and clinical settings.
• Provide a brief update on the pipeline program HLX22.
• Outline key R&D milestones over the next 6–12 months.

The R&D Day will be held as a live Teams webinar and will include a Q&A session. All participants will have the opportunity to submit questions in advance, via ir@alligatorbioscience.com, or during the event.

Event details
Date: Tuesday, 19 August 2025
Time: 4-5 p.m. CEST
Format: Virtual Teams webinar
Registration: Please use this link to register

A replay of the event will be made available on Alligator’s website after the webinar.